Drug intelligence / Profile preview

Staphylococcus multispecific antibodies

Development stage: Preclinical
Lead developer: Eliteimmune
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

Staphylococcus multispecific antibodies is a preclinical-stage program being developed by Eliteimmune, in collaboration with Integrated Biotherapeutics, for the prevention and treatment of Staphylococcal infections, including methicillin-resistant Staphylococcus aureus (MRSA). The therapeutic candidate consists of fully human, broadly neutralizing multispecific antibodies derived from vaccinated non-human primates and elite human donors. These antibodies are designed to target and neutralize multiple staphylococcal virulence factors (such as bacterial toxins) to combat drug-resistant S. aureus infections.

Other names: MRSA multispecific antibodiesStaph multispecific antibodies

Beyond the preview

Go deeper on Staphylococcus multispecific antibodies.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Staphylococcus multispecific antibodies.